Muscular atrophy is the thinning, wasting, or loss of muscle tissue, leading to decreased strength and mass. There are various types of muscle atrophy and different treatments for them.

The brain naturally begins to atrophy beginning in one’s 30s and 40s. But this can become much more pronounced with dementia ...

利司扑兰是由瑞士罗氏制药公司开发的运动神经元生存基因2（SMN2）剪接修饰剂，于2020年8月在美国获批，2021年6月在中国获批，是首个被批准用于SMA的口服治疗药物，作为全球首个获批的直接以RNA为靶点发挥作用的小分子药物，其作用机制是通过靶向屏 ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

A retrospective analysis on newborn screening for spinal muscular atrophy (SMA) provides further evidence for the benefits of early identification and treatment of the disease. A recent analysis ...

Public health groups are challenging Roche's attempt to block a generic version of its expensive Spinal Muscular Atrophy drug ...

You can still live a full life with geographic atrophy (GA). Even though your vision may be different, GA doesn’t lead to total blindness. You can use your remaining vision and make certain ...

Highlights:,Belite Bio doses first patient in Phase 2/3 DRAGON II trial for Stargardt disease.,$28.75 million raised from ...

Despite diagnostic and therapeutic advances, mortality and the multi-systemic health impact of SMA continue to be experienced ...

ADR presented to its investors. Belite Bio, Inc. ADR is a clinical-stage biopharmaceutical company focused on developing novel treatments for degenerative retinal diseases, specifically targeting ...

Muscle fibers in children with SMA type 1 show substantial differences in components of the myosin protein called heavy ...

Belite Bio, Inc. ( NASDAQ: BLTE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer Nathan Mata - Chief ...